Understanding Telix, page-1203

[18F]DCFPyL was assessed to be a suitable alternative to [68Ga]Ga-PSMA-11 in PCa diagnosis and staging due to its similar lesion uptake rate with no increase in benign uptakes. [18F]PSMA-1007 was assessed to be less preferrable to [68Ga]Ga-PSMA-11 due to its significant number of benign bone uptakes. Although [18F]PSMA-1007 was able to detect more locoregional lesions due to its lower urinary excretions, the use of diuretics prior to the scan facilitated [68Ga]Ga-PSMA-11 to achieve a similar local lesion detection rate in comparison to [18F]PSMA-1007. Overall, there was not enough evidence in differentiating [18F]DCFPyL and [68Ga]Ga-PSMA-11 in their clinical impacts. The decision to use [18F]DCFPyL or [68Ga]Ga-PSMA-11 is largely based on infrastructure available at the individual health service.

https://www.nature.com/articles/s41391-023-00755-2